"Tracking Baker Brothers Portfolio – Q4 2017 Update"
"Baker Brothers’ 13F portfolio value decreased from $12.33B to $11.54B. The number of positions increased from 121 to 123.BioMarin Pharmaceutical Stake was increased during the quarter.The top-three positions are Incyte Corporation, Seattle Genetics, and Alexion Pharmaceuticals and they add up to almost ~58% of the portfolio.This article is part of a series that provides an ongoing analysis of the changes made to Baker Brothers’ 13F portfolio on a quarterly basis. It is based on Baker Brothers’ regulatory  filed on 02/14/2018.This quarter, Baker Brothers’ 13F portfolio decreased ~6% from $12.33B to $11.54B. The number of holdings increased from 121 to 123. The top three holdings are at ~58% while the top five holdings are close to ~71% of the 13F assets: Incyte Corporation (INCY), Seattle Genetics (SGEN), Alexion Pharmaceuticals (ALXN), Acadia Pharmaceuticals (ACAD), and BioMarin Pharmaceuticals (BMRN).The spreadsheet below highlights changes to Baker Brothers’ 13F holdings in Q4 2017. For a look at how the portfolio has progressed, please see our :To learn more about how to profit from a strategy of following the best hedge fund picks, check out our book .Regulatory Filings thru 1/29/2018: 13D/A – 1/22/2018 – BGNE – BeiGene - 156M shares – 22.4% of business,  1/18/2018 – Form 4 – 2M shares purchased at $101, Form4 – 1/17/2018 – BLCM – Bellicum Pharma. -  around 800K shares disposed in the low-8s. 13G/A – 1/10/2018 – AKAO - Achaogen – 122K shares – 0.3% of business. Form 4 – 1/4/2018 – IDRA - Idera Pharma - ~29K shares acquired at $2.21 as a result of grants issued, Form 4 – 1/3/2018 – GHDX - Genomic Health – very small acquisition at $34.2, Form 4 – 1/3/2018 – INCY – small acquisition at $94.71, Form 4 – 11/29/2017 – ACAD – 39.4K shares acquired at $1.38 as a result of warrant exercise, Form 4 & 13D/A – 11/20/2017 – MRTX - Mirati Therapeutics – 1.9M shares acquired at $12.99 – warrant exercise – 2.7M shares – 9.99% of business, 13D – 11/16/2017 – ERYP - Erytech Pharma. – 4.9M shares – 27.3% of business – overall cost-basis is ~$24.50 (~3M shares in the public offering @ $23.26 & 1.8M shares for 47.5M before),"